Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study Evaluating The Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of UCB5857 in Healthy and Mild-to-Moderate Psoriatic Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Seletalisib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors UCB
- 17 Jun 2017 Results of human PK profile (from two phase I studies) along with in-vitro cell-based studies on blood samples presented at the 18th Annual Congress of the European League Against Rheumatism
- 04 Feb 2017 Results of two phase I studies (NCT02303509 and NCT02207595), published in the European Journal of Clinical Pharmacology
- 04 Dec 2014 New trial record